"Loading Stock Price & Valuation Data ..."
Unlock News Summary by Subscribing to iPick.ai Premium!
Ask anything related to KYMR. [ FAQ on what and how to ask] For non-KYMR questions, click the logo in the upper-right corner to return to the main page and ask there.
CEO:Dr. Nello Mainolfi M.D., Ph.D.
Headquarter: 500 North Beacon Street, 4th Floor, Watertown, MA, United States, 02472
Industry: Biotechnology, Employees: 218
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
My Watchlist
